Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
Status:
Completed
Trial end date:
2011-04-16
Target enrollment:
Participant gender:
Summary
The safety and efficacy of midostaurin (PKC412), a novel investigational drug, will be
evaluated on the basis of response rate, when administered to patients with aggressive
systemic mastocytosis (ASM) or mast cell leukemia (MCL)